Literature DB >> 10961879

Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily.

M Jandrot-Perrus1, S Busfield, A H Lagrue, X Xiong, N Debili, T Chickering, J P Le Couedic, A Goodearl, B Dussault, C Fraser, W Vainchenker, J L Villeval.   

Abstract

Injuries to the vessel wall and subsequent exposure of collagen from the subendothelial matrix result in thrombus formation. In physiological conditions, the platelet plug limits blood loss. However, in pathologic conditions, such as rupture of atherosclerotic plaques, platelet-collagen interactions are associated with cardiovascular and cerebral vascular diseases. Platelet glycoprotein VI (GPVI) plays a crucial role in collagen-induced activation and aggregation of platelets, and people who are deficient in GPVI suffer from bleeding disorders. Based on the fact that GPVI is coupled to the Fc receptor (FcR)-gamma chain and thus should share homology with the FcR chains, the genes encoding human and mouse GPVI were identified. They belong to the immunoglobulin (Ig) superfamily and share 64% homology at the protein level. Functional evidence demonstrating the identity of the recombinant protein with GPVI was shown by binding to its natural ligand collagen; binding to convulxin (Cvx), a GPVI-specific ligand from snake venom; binding of anti-GPVI IgG isolated from a patient; and association to the FcR-gamma chain. The study also demonstrated that the soluble protein blocks Cvx and collagen-induced platelet aggregation and that GPVI expression is restricted to megakaryocytes and platelets. Finally, human GPVI was mapped to chromosome 19, long arm, region 1, band 3 (19q13), in the same region as multiple members of the Ig superfamily. This work offers the opportunity to explore the involvement of GPVI in thrombotic disease, to develop alternative antithrombotic compounds, and to characterize the mechanism involved in GPVI genetic deficiencies. (Blood. 2000;96:1798-1807)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961879

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Authors:  Thomas J Povsic; Bruce A Sullenger; Steven L Zelenkofske; Christopher P Rusconi; Richard C Becker
Journal:  J Cardiovasc Transl Res       Date:  2010-11-16       Impact factor: 4.132

2.  Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1.

Authors:  Jenny U Johansson; William D Brubaker; Harold Javitz; Andrew W Bergen; Denise Nishita; Abhishek Trigunaite; Andrés Crane; Justine Ceballos; Diego Mastroeni; Andrea J Tenner; Marwan Sabbagh; Joseph Rogers
Journal:  Alzheimers Dement       Date:  2018-05-21       Impact factor: 21.566

3.  Aegyptin displays high-affinity for the von Willebrand factor binding site (RGQOGVMGF) in collagen and inhibits carotid thrombus formation in vivo.

Authors:  Eric Calvo; Fuyuki Tokumasu; Daniella M Mizurini; Peter McPhie; David L Narum; José Marcos C Ribeiro; Robson Q Monteiro; Ivo M B Francischetti
Journal:  FEBS J       Date:  2009-12-15       Impact factor: 5.542

4.  Functional expression of IgA receptor FcalphaRI on human platelets.

Authors:  Kun Qian; Fenglong Xie; Andrew W Gibson; Jeffrey C Edberg; Robert P Kimberly; Jianming Wu
Journal:  J Leukoc Biol       Date:  2008-09-10       Impact factor: 4.962

5.  Development of a genetic marker set to diagnose aspirin-exacerbated respiratory disease in a genome-wide association study.

Authors:  H S Chang; S W Shin; T H Lee; D J Bae; J S Park; Y H Kim; S T Uh; B W Choi; M K Kim; I S Choi; B L Park; H D Shin; C S Park
Journal:  Pharmacogenomics J       Date:  2015-02-24       Impact factor: 3.550

6.  Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.

Authors:  Phillip L R Nicolson; Craig E Hughes; Stephanie Watson; Sophie H Nock; Alexander T Hardy; Callum N Watson; Samantha J Montague; Hayley Clifford; Aarnoud P Huissoon; Jean-Daniel Malcor; Mark R Thomas; Alice Y Pollitt; Michael G Tomlinson; Guy Pratt; Steve P Watson
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

7.  Hematopoietic lineage cell specific protein 1 (HS1) is a functionally important signaling molecule in platelet activation.

Authors:  Bryan N Kahner; Robert T Dorsam; Sripal R Mada; Soochong Kim; Timothy J Stalker; Lawrence F Brass; James L Daniel; Daisuke Kitamura; Satya P Kunapuli
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

8.  A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex.

Authors:  Hiroshi Takayama; Yoshitaka Hosaka; Kazuyuki Nakayama; Kamon Shirakawa; Katsuki Naitoh; Tomokazu Matsusue; Mikihiko Shinozaki; Motoyasu Honda; Yukiko Yatagai; Tetsushi Kawahara; Jiro Hirose; Tooru Yokoyama; Michiru Kurihara; Shoji Furusako
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 9.  Role of cellular elements in thrombus formation and dissolution.

Authors:  N Wohner
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-07

10.  Neutrophil granulocyte-dependent proteolysis enhances platelet adhesion to the arterial wall under high-shear flow.

Authors:  N Wohner; Z Keresztes; P Sótonyi; L Szabó; E Komorowicz; R Machovich; K Kolev
Journal:  J Thromb Haemost       Date:  2010-04-20       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.